Skip to main content

Advertisement

SpringerLink
Log in

Bisphosphonates or prostacyclin in the treatment of bone-marrow oedema syndrome of the knee and foot

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Bone-marrow oedema (BME) represents a reversible but mostly painful increase in interstitial fluid. The exact pathogenetic processes still remain unknown. Treatment options are mainly symptomatic with core decompression as golden standard leading to immediate pain relieve. Recently, it has been shown that intravenous prostacyclin and bisphosphonates are useful in achieving a reduction in BME with a considerable improvement in the accompanying symptoms. We compared the outcome of both intravenously applied prostacyclin (Ilomedin®, 10 patients) and bisphosphonate (Bondronat®, 10 patients) in treatment of BME of the knee and foot. We could find a significant improvement of WOMAC score, SF-36 score and VAS 3 months and 1 year after therapeutic intervention in both the prostacyclin and the bisphosphonate group. Concerning the MRI scans in both groups, we found a distinct reduction of BME in 47 % and a complete regression in 40 %. Comparing both groups, the improvement of the scores was greater in the prostacyclin group than in the bisphosphonate group; the difference, however, was not significant. Intravenous bisphosphonates as well as prostacyclin are of efficient therapeutic benefit in treatment of BME with a quicker and greater effect of prostacyclin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Hofmann S, Kramer J, Breitenseher M, Pietsch M, Aigner N (2006) Bone marrow edema in the knee. Differential diagnosis and therapeutic possibilities. Orthopade 35(4):463–475

    Article  CAS  Google Scholar 

  2. Aigner N, Petje G, Steinboeck G, Schneider W, Krasny C, Landsiedl F (2001) Treatment of bone-marrow oedema of the talus with the prostacyclin analogue iloprost. An MRI-controlled investigation of a new method. J Bone Joint Surg Br 83(6):855–858

    Article  CAS  Google Scholar 

  3. Disch AC, Matziolis G, Perka C (2005) The management of necrosis-associated and idiopathic bone-marrow oedema of the proximal femur by intravenous iloprost. J Bone Joint Surg Br 87(4):560–564

    Article  CAS  Google Scholar 

  4. Meizer R, Radda C, Stolz G, Kotsaris S, Petje G, Krasny C, Wlk M, Mayerhöfer M, Landsiedl F, Aigner N (2005) MRI-controlled analysis of 104 patients with painful bone marrow edema in different joint localizations treated with the prostacyclin analogue iloprost. Wien Klin Wochenschr 117(7–8):278–286

    Article  Google Scholar 

  5. Guerra JJ, Steinberg ME (1995) Distinguishing transient osteoporosis from avascular necrosis of the hip. J Bone Joint Surg Am 77(4):616–624

    Article  CAS  Google Scholar 

  6. Hofmann S, Engel A, Neuhold A, Leder K, Kramer J, Plenk H Jr (1993) Bone-marrow oedema syndrome and transient osteoporosis of the hip. An MRI-controlled study of treatment by core decompression. J Bone Joint Surg Br 75(2):210–216

    Article  CAS  Google Scholar 

  7. Mont MA, Ragland PS, Etienne G (2004) Core decompression of the femoral head for osteonecrosis using percutaneous multiple small-diameter drilling. Clin Orthop Relat Res 429:131–138

    Article  Google Scholar 

  8. Apel DM, Vince KG, Kingston S (1994) Transient osteoporosis of the hip: a role for core decompression? Orthopedics 17(7):629–632

    CAS  PubMed  Google Scholar 

  9. Meizer R, Meraner D, Meizer E, Radda C, Landsiedl F, Aigner N (2009) Outcome of painful bone marrow edema of the femoral head following treatment with parenteral iloprost. Indian J Orthop 43(1):36–39

    Article  Google Scholar 

  10. Aigner N, Petje G, Schneider W, Meizer R, Wlk M, Kotsaris S, Knahr K, Landsiedl F (2005) Bone marrow edema syndrome of the femoral head: treatment with the prostacyclin analogue iloprost versus core decompression: an MRI-controlled study. Wien Klin Wochenschr 117(4):130–135

    Article  Google Scholar 

  11. Ramachandran M, Ward K, Brown RR, Munns CF, Cowell CT, Little DG (2007) Intravenous bisphosphonate therapy for traumatic osteonecrosis of the femoral head in adolescents. J Bone Joint Surg Am 89(8):1727–1734

    Article  Google Scholar 

  12. Ringe JD, Body JJ (2007) A review of bone pain relief with ibandronate and other bisphosphonates in disorders of increased bone turnover. Clin Exp Rheumatol 25(5):766–774

    CAS  PubMed  Google Scholar 

  13. Petje G, Radler C, Aigner N, Kriegs-Au G, Ganger R, Grill F (2002) Aseptic osteonecrosis in childhood: diagnosis and treatment. Orthopade 31(10):1027–1038

    Article  CAS  Google Scholar 

  14. Agarwala S, Jain D, Joshi VR, Sule A (2005) Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study. Rheumatology (Oxford) 44(3):352–359

    Article  CAS  Google Scholar 

  15. Grant SM, Goa KL (1992) Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures. Drugs 43(6):889–924

    Article  CAS  Google Scholar 

  16. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R (1998) Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339(14):947–952

    Article  CAS  Google Scholar 

  17. Ciana G, Cuttini M, Bembi B (1997) Short-term effects of pamidronate in patients with Gaucher’s disease and severe skeletal involvement. N Engl J Med 337(10):712

    Article  CAS  Google Scholar 

  18. Little DG, Smith NC, Williams PR, Briody JN, Bilston LE, Smith EJ, Gardiner EM, Cowell CT (2003) Zoledronic acid prevents osteopenia and increases bone strength in a rabbit model of distraction osteogenesis. J Bone Miner Res 18(7):1300–1307

    Article  CAS  Google Scholar 

  19. Little DG, Cornell MS, Briody J, Cowell CT, Arbuckle S, Cooke-Yarborough CM (2001) Intravenous pamidronate reduces osteoporosis and improves formation of the regenerate during distraction osteogenesis. A study in immature rabbits. J Bone Joint Surg Br 83(7):1069–1074

    Article  CAS  Google Scholar 

  20. Kim HK, Randall TS, Bian H, Jenkins J, Garces A, Bauss F (2005) Ibandronate for prevention of femoral head deformity after ischemic necrosis of the capital femoral epiphysis in immature pigs. J Bone Joint Surg Am 87(3):550–557

    Article  Google Scholar 

  21. Nishii T, Sugano N, Miki H, Hashimoto J, Yoshikawa H (2006) Does alendronate prevent collapse in osteonecrosis of the femoral head? Clin Orthop Relat Res 443:273–279

    Article  Google Scholar 

  22. Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P (2007) A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 29(8):1548–1558

    Article  CAS  Google Scholar 

  23. Tonino RP, Meunier PJ, Emkey R, Rodriguez-Portales JA, Menkes CJ, Wasnich RD, Bone HG, Santora AC, Wu M, Desai R, Ross PD (2000) Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III osteoporosis treatment study group. J Clin Endocrinol Metab 85(9):3109–3115

    CAS  PubMed  Google Scholar 

  24. Kim HK, Sanders M, Athavale S, Bian H, Bauss F (2006) Local bioavailability and distribution of systemically (parenterally) administered ibandronate in the infarcted femoral head. Bone 39(1):205–212

    Article  CAS  Google Scholar 

  25. Aigner N, Meizer R, Petje G, Meizer E, Abdelkafy A, Landsiedl F (2008) Natural course of intra-articular shifting bone marrow edema syndrome of the knee. BMC Musculoskelet Disord 11(9):45

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Orthopaedic Surgery, University Hospital of Regensburg, Bad Abbach, Germany

    Clemens Baier, Jens Schaumburger, Jürgen Götz, Guido Heers, Thorsten Schmidt, Joachim Grifka & Johannes Beckmann

Authors
  1. Clemens Baier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jens Schaumburger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jürgen Götz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Guido Heers
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Thorsten Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Joachim Grifka
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Johannes Beckmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Clemens Baier.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Baier, C., Schaumburger, J., Götz, J. et al. Bisphosphonates or prostacyclin in the treatment of bone-marrow oedema syndrome of the knee and foot. Rheumatol Int 33, 1397–1402 (2013). https://doi.org/10.1007/s00296-012-2584-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-012-2584-0

Keywords

Search

Navigation